TriLink, Maravai LifeSciences unit, opens GMP enzyme manufacturing facility in Florida

Maravai Lifesciences Holdings, Inc. Class A

Maravai Lifesciences Holdings, Inc. Class A

MRVI

0.00

  • Maravai LifeSciences unit TriLink opened a GMP enzyme manufacturing facility in Jupiter, Florida to support RNA therapeutics production from R&D to commercial scale.
  • TriLink aims to consolidate sourcing of key IVT raw materials under one supplier, reducing multi-vendor quality and logistics risk.
  • Facility shipped its first commercial GMP enzyme batch in June 2026, marking readiness for commercial-scale supply.
  • Flagship output includes GMP CleanScribe RNA Polymerase, designed to cut dsRNA formation by up to 85% versus wild-type T7 polymerase.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606160830BIZWIRE_USPR_____20260616_BW862149) on June 16, 2026, and is solely responsible for the information contained therein.